LT5524B - Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas - Google Patents
Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas Download PDFInfo
- Publication number
- LT5524B LT5524B LT2008003A LT2008003A LT5524B LT 5524 B LT5524 B LT 5524B LT 2008003 A LT2008003 A LT 2008003A LT 2008003 A LT2008003 A LT 2008003A LT 5524 B LT5524 B LT 5524B
- Authority
- LT
- Lithuania
- Prior art keywords
- meldonium
- pharmaceutical composition
- lamivudine
- reverse transcriptase
- stavudine
- Prior art date
Links
- PVBQYTCFVWZSJK-UHFFFAOYSA-N meldonium Chemical compound C[N+](C)(C)NCCC([O-])=O PVBQYTCFVWZSJK-UHFFFAOYSA-N 0.000 title claims abstract description 146
- 229960002937 meldonium Drugs 0.000 title claims abstract description 143
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 53
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 title claims abstract description 29
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims abstract description 106
- 229960002555 zidovudine Drugs 0.000 claims abstract description 99
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims abstract description 90
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims abstract description 89
- 229960001203 stavudine Drugs 0.000 claims abstract description 89
- 229960001627 lamivudine Drugs 0.000 claims abstract description 88
- 206010029350 Neurotoxicity Diseases 0.000 claims abstract 2
- 206010044221 Toxic encephalopathy Diseases 0.000 claims abstract 2
- 230000007135 neurotoxicity Effects 0.000 claims abstract 2
- 231100000228 neurotoxicity Toxicity 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 8
- 230000006676 mitochondrial damage Effects 0.000 claims description 7
- 238000007911 parenteral administration Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 102100034343 Integrase Human genes 0.000 claims description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 206010067484 Adverse reaction Diseases 0.000 claims description 3
- 230000006838 adverse reaction Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000008188 pellet Substances 0.000 claims 2
- 230000007681 cardiovascular toxicity Effects 0.000 claims 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 206010048610 Cardiotoxicity Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 210000004413 cardiac myocyte Anatomy 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 102000003945 NF-kappa B Human genes 0.000 description 8
- 108010057466 NF-kappa B Proteins 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000005003 heart tissue Anatomy 0.000 description 7
- 210000003470 mitochondria Anatomy 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229960004203 carnitine Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000002438 mitochondrial effect Effects 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000021642 Muscular disease Diseases 0.000 description 4
- 201000009623 Myopathy Diseases 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 229940120938 zidovudine and lamivudine Drugs 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000798 anti-retroviral effect Effects 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 230000003562 morphometric effect Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 230000035806 respiratory chain Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 235000010582 Pisum sativum Nutrition 0.000 description 2
- 240000004713 Pisum sativum Species 0.000 description 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 206010038997 Retroviral infections Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940124522 antiretrovirals Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003293 cardioprotective effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000007491 morphometric analysis Methods 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012764 semi-quantitative analysis Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- -1 2: 1 Chemical compound 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 1
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000282554 Erythrocebus Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241001575049 Sonia Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000004099 anaerobic respiration Effects 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000009352 congenital transmission Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 231100000351 embryotoxic Toxicity 0.000 description 1
- 230000001779 embryotoxic effect Effects 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940029101 lamivudine 300 mg Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000010021 mitochondrial pathology Effects 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LVP-05-95A LV13544B (en) | 2005-08-15 | 2005-08-15 | Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT2008003A LT2008003A (en) | 2008-07-25 |
| LT5524B true LT5524B (lt) | 2008-10-27 |
Family
ID=37442067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT2008003A LT5524B (lt) | 2005-08-15 | 2008-01-18 | Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7700576B2 (uk) |
| EP (1) | EP1933823B1 (uk) |
| JP (1) | JP5027809B2 (uk) |
| CN (1) | CN101252925B (uk) |
| AR (1) | AR066995A1 (uk) |
| AT (1) | ATE493123T1 (uk) |
| DE (1) | DE602006019293D1 (uk) |
| EE (1) | EE05529B1 (uk) |
| ES (1) | ES2361185T3 (uk) |
| HN (1) | HN2006029085A (uk) |
| LT (1) | LT5524B (uk) |
| LV (1) | LV13544B (uk) |
| PE (1) | PE20070233A1 (uk) |
| SV (1) | SV2007002655A (uk) |
| UA (1) | UA90162C2 (uk) |
| UY (1) | UY29751A1 (uk) |
| WO (1) | WO2007021164A1 (uk) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1009600A2 (uk) * | 2009-06-25 | 2016-03-22 | Tetra S A | |
| LV14848B (lv) * | 2012-10-25 | 2015-06-20 | Latvijas Organiskās Sintēzes Institūts | Farmaceitiska kompozīcija trimetilamīna-N-oksīda līmeņa pazemināšanai |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4481218A (en) | 1978-11-27 | 1984-11-06 | Institut Organicheskogo Sinteza Akademii Nauk Latviiskoi Ssr | 3-(2,2,2-Trimethylhydrazinium)propionate and method for the preparation and use thereof |
| US4724232A (en) | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
| WO1991017159A1 (en) | 1990-05-02 | 1991-11-14 | Iaf Biochem International Inc. | 1,3-oxathiolane nucleoside analogues |
| US5130421A (en) | 1988-03-24 | 1992-07-14 | Bristol-Myers Company | Production of 2',3'-dideoxy-2',3'-didehydronucleosides |
| EP0560275A1 (en) | 1992-03-11 | 1993-09-15 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Use of L-carnitine for treating carnitine-depleted HIV-seropositive patients |
-
2005
- 2005-08-15 LV LVP-05-95A patent/LV13544B/lv unknown
-
2006
- 2006-08-08 DE DE602006019293T patent/DE602006019293D1/de active Active
- 2006-08-08 US US11/990,285 patent/US7700576B2/en not_active Expired - Fee Related
- 2006-08-08 EE EEP200800014A patent/EE05529B1/xx not_active IP Right Cessation
- 2006-08-08 JP JP2008526897A patent/JP5027809B2/ja not_active Expired - Fee Related
- 2006-08-08 WO PCT/LV2006/000005 patent/WO2007021164A1/en not_active Ceased
- 2006-08-08 UA UAA200803268A patent/UA90162C2/uk unknown
- 2006-08-08 EP EP06783790A patent/EP1933823B1/en active Active
- 2006-08-08 AT AT06783790T patent/ATE493123T1/de not_active IP Right Cessation
- 2006-08-08 ES ES06783790T patent/ES2361185T3/es active Active
- 2006-08-08 CN CN2006800298828A patent/CN101252925B/zh not_active Expired - Fee Related
- 2006-08-11 AR ARP060103527A patent/AR066995A1/es unknown
- 2006-08-14 UY UY29751A patent/UY29751A1/es not_active Application Discontinuation
- 2006-08-14 PE PE2006000983A patent/PE20070233A1/es not_active Application Discontinuation
- 2006-08-15 HN HN2006029085A patent/HN2006029085A/es unknown
- 2006-08-15 SV SV2006002655A patent/SV2007002655A/es not_active Application Discontinuation
-
2008
- 2008-01-18 LT LT2008003A patent/LT5524B/lt not_active IP Right Cessation
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4481218A (en) | 1978-11-27 | 1984-11-06 | Institut Organicheskogo Sinteza Akademii Nauk Latviiskoi Ssr | 3-(2,2,2-Trimethylhydrazinium)propionate and method for the preparation and use thereof |
| US4724232A (en) | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
| US5130421A (en) | 1988-03-24 | 1992-07-14 | Bristol-Myers Company | Production of 2',3'-dideoxy-2',3'-didehydronucleosides |
| WO1991017159A1 (en) | 1990-05-02 | 1991-11-14 | Iaf Biochem International Inc. | 1,3-oxathiolane nucleoside analogues |
| EP0560275A1 (en) | 1992-03-11 | 1993-09-15 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Use of L-carnitine for treating carnitine-depleted HIV-seropositive patients |
Non-Patent Citations (2)
| Title |
|---|
| BROCKLEHURST P, VOLMINK J.: "Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.", COCHRANE DATABASE SYST REV., 2002, pages 003510 |
| LEWIS W. ET AL.: "Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria", J. CLIN. INVEST., 1992, pages 1354 - 1360, XP002963913, DOI: doi:10.1172/JCI115722 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20090137522A1 (en) | 2009-05-28 |
| EP1933823A1 (en) | 2008-06-25 |
| EE200800014A (et) | 2008-06-16 |
| UY29751A1 (es) | 2007-03-30 |
| LT2008003A (en) | 2008-07-25 |
| DE602006019293D1 (de) | 2011-02-10 |
| CN101252925B (zh) | 2012-04-25 |
| SV2007002655A (es) | 2007-04-12 |
| WO2007021164A1 (en) | 2007-02-22 |
| JP2009504731A (ja) | 2009-02-05 |
| HN2006029085A (es) | 2007-11-16 |
| UA90162C2 (uk) | 2010-04-12 |
| EE05529B1 (et) | 2012-04-16 |
| AR066995A1 (es) | 2009-09-30 |
| US7700576B2 (en) | 2010-04-20 |
| ES2361185T3 (es) | 2011-06-14 |
| LV13544B (en) | 2007-05-20 |
| JP5027809B2 (ja) | 2012-09-19 |
| PE20070233A1 (es) | 2007-06-08 |
| ATE493123T1 (de) | 2011-01-15 |
| CN101252925A (zh) | 2008-08-27 |
| EP1933823B1 (en) | 2010-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20020169140A1 (en) | Combination therapy for reduction of toxicity of chemotherapeutic agents | |
| US5719132A (en) | Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil | |
| Barditch-Crovo et al. | Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl] adenine) in HIV-infected patients | |
| US10369166B2 (en) | Pharmaceutical compositions for treating ebola virus disease | |
| JP2017141308A (ja) | 細胞内ａｔｐ増強剤 | |
| EP1272897B1 (en) | Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver | |
| AU2001238124A1 (en) | Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis,cirrhosis and fatty liver | |
| WO2021205437A1 (en) | Pharmaceutical compositions for treating corona virus disease | |
| LT5524B (lt) | Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas | |
| AU755633B2 (en) | Antiviral combinations | |
| EP0839033B1 (en) | Use of l-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral | |
| Lemberg et al. | Tolerabilities of antiretrovirals in paediatric HIV infection | |
| TWI324927B (en) | Pharmaceutical composition on basis of reverse transcriptase inhibitor and meldonium | |
| MXPA03005382A (es) | Terapia combinada de dapd con un inhibidor de inosino monofosfato dehidrogenasa. | |
| US7745455B2 (en) | Zalcitabine (ddC) boosted lamivudine (3TC) compositions for antiretroviral therapy | |
| EP1113803A1 (en) | Antiviral combinations comprising lamivudine and abacavir | |
| JP7414230B2 (ja) | 抗血液悪性腫瘍薬 | |
| RU106840U1 (ru) | Диспергируемая в воде лекарственная таблетка противотуберкулезного действия | |
| Blonk | Clinical pharmacology of the HIV integrase inhibitor raltegravir: drug-drug interactions and pharmacokinetics | |
| US20170246241A1 (en) | Methods for the Selective Treatment of Tumors by Calcium-Mediated Induction of Apoptosis | |
| KR20230044481A (ko) | 감기약 및 항바이러스제 | |
| HK1246165B (zh) | 细胞内atp增强剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM9A | Lapsed patents |
Effective date: 20140808 |